Intermittent chemotherapy for miliary tuberculosis in children

Area of Science:

• Pediatric infectious diseases
• Pulmonology
• Microbiology

Background:

• Miliary tuberculosis is a severe disseminated form of tuberculosis.
• Effective and safe treatment regimens are crucial for pediatric patients.
• Optimizing treatment duration and drug delivery is an ongoing challenge.

Purpose of the Study:

• To evaluate the safety and efficacy of intermittent antituberculous therapy in children diagnosed with miliary tuberculosis.
• To assess treatment outcomes, including clinical and radiological clearance, drug toxicity, resistance, and relapse rates.

Main Methods:

• A cohort of six pediatric patients diagnosed with miliary tuberculosis was treated.
• Intermittent antituberculous therapy was administered for treatment durations of six, nine, or 12 months.
• Patients were monitored for clinical and radiological symptoms, drug toxicity, resistance, and relapses during follow-up periods ranging from nine months to nine years.

Main Results:

• All six patients achieved complete clearance of both clinical and radiological symptoms.
• No instances of drug toxicity or resistance were observed.
• No relapses occurred during the extended follow-up period.

Conclusions:

• Intermittent antituberculous therapy is a safe and effective treatment strategy for pediatric miliary tuberculosis.
• This regimen presents a viable alternative due to its minimal toxicity and reduced cost.
• Long-term follow-up confirms sustained efficacy and absence of relapses.